MDGL vs LLY

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus 44. 7% for Eli Lilly and Company (LLY). Eli Lilly and Company (LLY) offers the better valuation at 43. 0x trailing P/E (28. 6x forward), making it the more compelling value choice. Analysts rate Madrigal Pharmaceuticals, Inc. (MDGL) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +421.

4%, compared to +326. 0% for Madrigal Pharmaceuticals, Inc. (MDGL). Over 10 years, the gap is even starker: MDGL returned +37. 6% versus LLY's +1272%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Madrigal Pharmaceuticals, Inc.

(MDGL) is the lower-risk stock at 0. 57β versus Eli Lilly and Company's 0. 71β — meaning LLY is approximately 25% more volatile than MDGL relative to the S&P 500. On balance sheet safety, Madrigal Pharmaceuticals, Inc. (MDGL) carries a lower debt/equity ratio of 59% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus 44. 7% for Eli Lilly and Company (LLY). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to 41. 3% for Madrigal Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -30. 1% for Madrigal Pharmaceuticals, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -31. 3% for MDGL. At the gross margin level — before operating expenses — MDGL leads at 94. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MDGL: 30.

7% to $705. 67.

In this comparison, LLY (0.

6% yield) pays a dividend. MDGL does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71), 0. 6% yield, +1272% 10Y return). Both have compounded well over 10 years (LLY: +1272%, MDGL: +37. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

LLY pays a dividend while MDGL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.